Ballesteros M, Leung K C, Ross R J, Iismaa T P, Ho K K
Pituitary Research Unit, Garvan Institute of Medical Research, St Vincent's Hospital, Sydney, New South Wales, Australia.
J Clin Endocrinol Metab. 2000 Aug;85(8):2865-71. doi: 10.1210/jcem.85.8.6711.
Two alternatively spliced exon 9 variants of human GH receptor (GHR) messenger ribonucleic acid (mRNA), GHR-(1-279) and GHR(1-277), were recently identified in liver. They encode receptor proteins lacking most of the intracellular domain and inhibit GH action in a dominant negative manner. Little is known about tissue distribution and abundance of these GHR isoforms. We have developed quantitative RT-PCR assays specific for the full-length and truncated GHRs and investigated their expression in various human tissues and cell lines. The mRNA of full-length GHR and GHR-(1-279) were readily detectable in all tissues investigated, with liver, fat, muscle, and kidney showing high levels of expression. These two receptor isoforms were also detected in a range of human cell lines, with strongest expression in IM9, a lymphoblastoid cell line. In contrast, GHR-(1277) message was expressed at low levels in liver, fat, muscle, kidney, and prostate and in trace amount in IM9 cells. Full-length GHR was the most abundant isoform, accounting for over 90% of total receptor transcripts in liver, fat, and muscle for quantitative RT-PCR. However, liver had 2- to 4-fold more full-length receptor mRNA and 16- to 40-fold more GHR-(1-277) mRNA than fat and muscle, whereas the mRNA levels of GHR-(1-279) were similar in the three tissues. GHR-(1-279) constituted less than 4% in liver and 7-10% in fat and muscle. GHR-(1-277) accounted for 0.5% of total GHR transcripts in liver and less than 0.1% in the other two tissues. These data suggest that the absolute and relative abundance of mRNA of the three GHR isoforms may be tissue specific. The regulation of expression of exon 9 alternatively spliced GHR variants may provide a potential mechanism for modulation of GH sensitivity at the tissue level.
最近在肝脏中发现了人类生长激素受体(GHR)信使核糖核酸(mRNA)的两种选择性剪接外显子9变体,即GHR-(1-279)和GHR(1-277)。它们编码的受体蛋白缺乏大部分细胞内结构域,并以显性负性方式抑制生长激素的作用。关于这些GHR异构体的组织分布和丰度知之甚少。我们开发了针对全长和截短型GHR的定量逆转录聚合酶链反应(RT-PCR)检测方法,并研究了它们在各种人类组织和细胞系中的表达情况。在所有研究的组织中都很容易检测到全长GHR和GHR-(1-279)的mRNA,肝脏、脂肪、肌肉和肾脏显示出高水平的表达。这两种受体异构体也在一系列人类细胞系中被检测到,在淋巴母细胞系IM9中表达最强。相比之下,GHR-(1277)的信使RNA在肝脏、脂肪、肌肉、肾脏和前列腺中低水平表达,在IM9细胞中微量表达。全长GHR是最丰富的异构体,在肝脏、脂肪和肌肉中,定量RT-PCR检测显示其占总受体转录本的90%以上。然而,肝脏中全长受体mRNA比脂肪和肌肉多2至4倍,GHR-(1-277) mRNA比脂肪和肌肉多16至40倍,而GHR-(1-279)的mRNA水平在这三种组织中相似。GHR-(1-279)在肝脏中占比不到4%,在脂肪和肌肉中占7-10%。GHR-(1-277)在肝脏中占总GHR转录本的0.5%,在其他两种组织中不到0.1%。这些数据表明,三种GHR异构体mRNA的绝对丰度和相对丰度可能具有组织特异性。外显子9选择性剪接的GHR变体表达的调控可能为在组织水平调节生长激素敏感性提供一种潜在机制。